Sustainable Access to Plasma-Derived Medicinal Products: A Resilience-Informed Approach to Cost-Containment

For patients who depend on plasma-derived medicinal products (PDMPs), sustainable access is not an abstract supply-chain objective. It determines whether infections are prevented, bleeding is controlled, neurological deterioration is avoided, treatment can continue at home or in hospital, and patients can maintain independence, live, function, work, study and participate in family and societal life with dignity.‍

‍